Clinical Trials Sponsored by Merck KGaA

Total 5034 results

Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)

Obesity | Overweight | Body Weight
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) (MODIFY I)

Clostridium Difficile Infection
Merck Sharp & Dohme LLC

Completed

Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

Hepatic Insufficiency
Merck Sharp & Dohme LLC

Terminated

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)

Benign Prostatic Hyperplasia
Merck Sharp & Dohme LLC

Completed

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)

Renal Insufficiency
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Odanacatib (0822-059)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

Candidiasis, Invasive | Aspergillosis | Candidiasis, Esophageal
Merck Sharp & Dohme LLC

Terminated

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Neoplasms | Bone Cancer | Neuroblastoma | Solid Tumors | Kidney Tumor
Merck Sharp & Dohme LLC

Terminated

Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)

Leukemia, Lymphocytic, Acute | Myelogenous Leukemia, Acute | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Myelogenous Leukemia, Chronic, Aggressive Phase
Merck Sharp & Dohme LLC

Terminated

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) (EVADE)

Nausea | Vomiting
Merck Sharp & Dohme LLC

Terminated

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)

Acute Myelogenous Leukemia (AML)
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Colorectal Cancer
Merck Sharp & Dohme LLC

Terminated

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Neoplasms
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

ProQuad® Intramuscular vs Subcutaneous

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)

Intra-abdominal Infection | Complicated Intra-abdominal Infection
Merck Sharp & Dohme LLC

Completed

A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Papillomavirus Infections | Human
Merck Sharp & Dohme LLC

Completed

A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110)

Diabetes
Merck Sharp & Dohme LLC

Completed

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Solid Tumors
Merck Sharp & Dohme LLC

Completed

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101) (DANCHEONG)

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) (DISCOVER)

Ocular Hypertension | Open Angle Glaucoma
Merck Sharp & Dohme LLC

Completed

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

Glaucoma
Merck Sharp & Dohme LLC

Terminated

Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) (STOP)

Breast Neoplasm | Brain Neoplasm | Second Neoplasm
Merck Sharp & Dohme LLC

Terminated

Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Large Cell
Merck Sharp & Dohme LLC

Completed

Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)

Glioma
Merck Sharp & Dohme LLC

Completed

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

Melanoma
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

Chemotherapy-Induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Diabetes Mellitus, Non-Insulin-Dependent

3

Subscribe